New combo therapy aims to stop kidney damage in membranous nephropathy
NCT ID NCT00977977
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high protein in their urine will receive both drugs over 6 months, with follow-up for up to 2 years. The goal is to see if this combo can help more patients achieve remission and protect their kidneys from further damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab and cyclosporine
What this could lead to
If successful, this combination could offer a new treatment option for membranous nephropathy, potentially reducing protein in urine and protecting kidney function.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Both drugs suppress the immune system, which can increase infection risk and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
-
National Naval Medical Center
RECRUITINGBethesda, Maryland, 20889, United States